

May 22, 2024

## SciBase publishes the Annual report for 2023

SciBase hereby announces that the Annual report for 2023 is available at the Company's website [www.scibase.com](http://www.scibase.com).

A pdf-version of the annual report is enclosed to this press-release.

A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy.

**For more information, please contact:**

Michael Colérus, CFO

Tel: +46 70 341 34 72

E-mail: [michael.colerus@scibase.com](mailto:michael.colerus@scibase.com)

**Certified Advisor:**

Vator Securities

Tel: +46 580 065 99

Email: [ca@vatorsec.se](mailto:ca@vatorsec.se)

*The information was submitted for publication, through the agency of the contact person set out above, at 09.00 CET on May 22, 2024.*

**About SciBase and Nevisense**

*SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.*

*Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.*

*Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.*

*The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at [www.scibase.com](http://www.scibase.com). All press releases and financial reports can be found here: <http://investors.scibase.se/en/pressreleases>*